AP2003002795A0 - Oxidized proteins their biological activity and therapeutic and diagonistic measures which are derived from the active mechanism from the use of theseproteins or from the inhibition thereof - Google Patents

Oxidized proteins their biological activity and therapeutic and diagonistic measures which are derived from the active mechanism from the use of theseproteins or from the inhibition thereof

Info

Publication number
AP2003002795A0
AP2003002795A0 AP2003002795A AP2003002795A AP2003002795A0 AP 2003002795 A0 AP2003002795 A0 AP 2003002795A0 AP 2003002795 A AP2003002795 A AP 2003002795A AP 2003002795 A AP2003002795 A AP 2003002795A AP 2003002795 A0 AP2003002795 A0 AP 2003002795A0
Authority
AP
ARIPO
Prior art keywords
theseproteins
diagonistic
inhibition
therapeutic
measures
Prior art date
Application number
AP2003002795A
Other versions
AP2034A (en
Original Assignee
Kehrel B
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10051983A external-priority patent/DE10051983A1/en
Priority claimed from DE2001148624 external-priority patent/DE10148624A1/en
Application filed by Kehrel B filed Critical Kehrel B
Publication of AP2003002795A0 publication Critical patent/AP2003002795A0/en
Application granted granted Critical
Publication of AP2034A publication Critical patent/AP2034A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
APAP/P/2003/002795A 2000-10-20 2001-10-19 Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof. AP2034A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10051983A DE10051983A1 (en) 2000-10-20 2000-10-20 Medicaments useful e.g. for preventing thrombosis, inhibiting transplant rejection or treating chronic inflammatory reactions comprises agents inhibiting binding of oxidized proteins to CD36,
DE2001148624 DE10148624A1 (en) 2001-10-02 2001-10-02 Medicaments useful e.g. for preventing thrombosis, inhibiting transplant rejection or treating chronic inflammatory reactions comprises agents inhibiting binding of oxidized proteins to CD36,
PCT/EP2001/012129 WO2002032445A2 (en) 2000-10-20 2001-10-19 Inhibition of the interaction between oxidized proteins and cd36 or the active mechanism thereof

Publications (2)

Publication Number Publication Date
AP2003002795A0 true AP2003002795A0 (en) 2003-06-30
AP2034A AP2034A (en) 2009-08-28

Family

ID=26007431

Family Applications (2)

Application Number Title Priority Date Filing Date
AP2009004857A AP2781A (en) 2000-10-20 2001-10-19 Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechansim, from the use of these porteins or from the inhibition thereof
APAP/P/2003/002795A AP2034A (en) 2000-10-20 2001-10-19 Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AP2009004857A AP2781A (en) 2000-10-20 2001-10-19 Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechansim, from the use of these porteins or from the inhibition thereof

Country Status (14)

Country Link
EP (2) EP1328289B1 (en)
JP (1) JP4881535B2 (en)
AP (2) AP2781A (en)
AT (1) ATE406908T1 (en)
AU (1) AU2002215032A1 (en)
CA (1) CA2453140C (en)
CY (1) CY1110418T1 (en)
DE (1) DE50114289D1 (en)
DK (1) DK1328289T3 (en)
ES (1) ES2307662T3 (en)
HK (1) HK1057857A1 (en)
OA (1) OA12431A (en)
PT (1) PT1328289E (en)
WO (1) WO2002032445A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1684868T1 (en) * 2003-04-25 2012-05-31 Hambruger Stiftung Zur Foerderung Von Wissensachaft Und Kultur Treatment of hiv infections with hypochlorous acid-oxidised human blood plasma
KR20150013353A (en) * 2005-09-16 2015-02-04 코넬 리서치 화운데이션,인크. Methods for reducing cd36 expression
JP2010235447A (en) * 2007-07-30 2010-10-21 Igaku Seibutsugaku Kenkyusho:Kk Inhibitory agent for inflammatory cytokine
DE102010043733A1 (en) 2010-11-10 2012-05-10 Oxprotect Gmbh Unloaded PEGylated liposomes for use as medicaments for the prophylaxis and therapy of hemorrhagic and thromboembolic disorders
DE102011003936A1 (en) 2011-02-10 2012-08-16 Oxprotect Gmbh Use of proteins / peptides that bind to GRP78 (BIP) in laboratory methods for monitoring platelet aggregation inhibitors
DE102011003944A1 (en) 2011-02-10 2012-08-16 Oxprotect Gmbh Detection and removal of misfolded proteins / peptides
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3819923A1 (en) * 1988-06-11 1989-12-21 Behringwerke Ag FIBRINE (OGEN) DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
WO1991004744A1 (en) * 1989-10-06 1991-04-18 The Beth Israel Hospital Association Methods and apparatus for treating disease states using oxidized lipoproteins
US5192264A (en) * 1989-10-06 1993-03-09 The Beth Israel Hospital Association Methods and apparatus for treating disease states using oxidized lipoproteins
JPH0780906B2 (en) * 1990-01-08 1995-08-30 シェリング・コーポレーション Oxidized mutant of GM-CSF
EP0539506A4 (en) * 1990-07-18 1993-11-24 The Beth Israel Hospital Association Method for treating viral infections using oxidized lipoproteins
US5756067A (en) 1993-11-08 1998-05-26 Peptide Delivery Systems Pty Ltd Labelled diagnostic compositions and method of their use
RU2089179C1 (en) * 1995-12-14 1997-09-10 Закрытое акционерное общество "ВАМ" Stimulator of cytokin and hemopoietic factors production and a method of its using
AU3442397A (en) 1997-06-20 1999-01-04 Leuven Research & Development Vzw Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins
GB9806632D0 (en) * 1998-03-28 1998-05-27 Stevenson Robert Peptide factor
CA2348685A1 (en) * 1998-11-06 2000-05-18 Emory University Biomarkers for oxidative stress
DE10045047A1 (en) * 2000-09-12 2002-03-21 Beate Kehrel Medicament containing activated antithrombin III

Also Published As

Publication number Publication date
WO2002032445A3 (en) 2003-04-17
DK1328289T3 (en) 2008-12-15
AP2009004857A0 (en) 2009-06-30
CA2453140C (en) 2016-01-05
EP1328289A2 (en) 2003-07-23
ATE406908T1 (en) 2008-09-15
EP1328289B1 (en) 2008-09-03
CY1110418T1 (en) 2015-04-29
AP2034A (en) 2009-08-28
AP2781A (en) 2013-10-31
JP2004511526A (en) 2004-04-15
EP1994941A3 (en) 2012-07-25
AU2002215032A1 (en) 2002-04-29
DE50114289D1 (en) 2008-10-16
OA12431A (en) 2006-04-19
PT1328289E (en) 2008-12-10
ES2307662T3 (en) 2008-12-01
HK1057857A1 (en) 2004-04-23
WO2002032445A2 (en) 2002-04-25
JP4881535B2 (en) 2012-02-22
EP1994941A2 (en) 2008-11-26
CA2453140A1 (en) 2002-04-25

Similar Documents

Publication Publication Date Title
HUP0203563A3 (en) Fungicidal combinations of active substances and use thereof
ATE318590T1 (en) DRUG COMBINATIONS (E.G. CHLORPROMAZINE AND PENTAMIDINE) FOR THE THERAPY OF NEOPLASTIC DISEASES
NO20022974L (en) Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease
DE60020367D1 (en) AIRFUL CLOTHING FOR INCREASING THE COMFORT OF THE HUMAN BODY
NO995137L (en) Preparation of Highly Active Catalysts; the catalysts and their use
ATE318895T1 (en) HUMAN DELTA 5 DESATURASE GENE
AU2002320185A1 (en) Biological activity of ak155
MXPA02004770A (en) Therapeutic compositions and methods of use thereof.
IL143699A0 (en) Use of polypeptides or nucleic acids for the diagnosis or treatment of skin disorders and wound healing and for the identification of pharmacologically active substances
GB0019302D0 (en) Biological materials and the use thereof for the treatment of disease
AP2003002795A0 (en) Oxidized proteins their biological activity and therapeutic and diagonistic measures which are derived from the active mechanism from the use of theseproteins or from the inhibition thereof
MXPA03006776A (en) Use of il-18 inhibitors for the treatment and/or prevention of heart disease.
IL152202A0 (en) Human kcnq5 polypeptide and pharmaceutical compositions containing the same
EP1200133A4 (en) Manipulation of tissue or organ type using the notch pathway
GB9929497D0 (en) Improved amino acid mixtures for the treatment and/or management of certain diseases
GB9907553D0 (en) Purification of biological preparations
ZA200203269B (en) Nucleic acids of the human ABC1 gene and their therapeutic and diagnostic application.
AU2001240820A1 (en) Proteins, genes and their use for diagnosis and treatment of vascular dementia
GB9908059D0 (en) Diagnosis and treatment of diseases
NO20021713D0 (en) Self-cutting RNA sequences and their use for the control of protein synthesis
EP1306432A4 (en) Human ii type 5 alpha-reductase promoter gene and use thereof
AU2002222308A1 (en) Proteins, genes and their use for diagnosis and treatment of vascular response
IL155907A0 (en) Specific promotor of the human vascular endothelial cadherin-2-(hve-cad-2) gene and the therapeutic uses thereof
EP1549664A4 (en) Murine ortholog of the human disrupted-in-schizophrenia 1 gene
ZA200103250B (en) The treatment of immunomodulatory related and other diseases or conditions.